Breaking

Indian Teenager Killed in Central Park Carriage Horse Accident US Lifts Blockade on Iranian Ports as Ceasefire Agreement Takes Effect AI Inference Startup Baseten Nears $1.5 Billion Funding at $13 Billion Valuation Google's Android Developer Verification System Rolls Out This Year Apple Patches High-Severity Vulnerability in Beats Studio Buds NASA's HALO Lunar Module Development Halted, Sources Say Snap Spinoffs Dotmo to Focus on Generative AI for Gaming OpenAI Hires Google AI Legend Noam Shazeer and Former Trump White House Official Dean Ball TechCrunch's Top YC Spring 2026 Startups: Defense Tech, AI Agents, and High Valuations Trump Pressures Senate Republicans on Intelligence Leadership Indian Teenager Killed in Central Park Carriage Horse Accident US Lifts Blockade on Iranian Ports as Ceasefire Agreement Takes Effect AI Inference Startup Baseten Nears $1.5 Billion Funding at $13 Billion Valuation Google's Android Developer Verification System Rolls Out This Year Apple Patches High-Severity Vulnerability in Beats Studio Buds NASA's HALO Lunar Module Development Halted, Sources Say Snap Spinoffs Dotmo to Focus on Generative AI for Gaming OpenAI Hires Google AI Legend Noam Shazeer and Former Trump White House Official Dean Ball TechCrunch's Top YC Spring 2026 Startups: Defense Tech, AI Agents, and High Valuations Trump Pressures Senate Republicans on Intelligence Leadership

METiS TechBio

Steady3 stories2 sourcesLast updated: 6/7/2026

Related TopicsAI cellular reprogramming longevity anti-aging nano-delivery biotech Hong Kong stock market AI-driven drug design

Latest Stories

AI Startup Aims to Reverse Aging by Reprogramming Cells

6/7/2026AI summary

AI Startup Aims to Reverse Aging by Reprogramming Cells

An AI startup has raised $269.5M in an IPO to develop AI-driven nano-delivery systems for cellular reprogramming, aiming to reverse aging by restoring immune cell function, with the US leading global longevity investments at $8.49B in 2024.

METiS TechBio debuts on Hong Kong stock market with 173% surge

5/13/2026AI summary

METiS TechBio debuts on Hong Kong stock market with 173% surge

METiS TechBio's shares surged 173% on their Hong Kong debut, with the AI-driven drug design start-up raising HK$2.11 billion from its initial public offering

METiS TechBio Debuts Strongly on Hong Kong Stock Market, Drawing SpaceX Comparison

5/13/2026AI summary

METiS TechBio Debuts Strongly on Hong Kong Stock Market, Drawing SpaceX Comparison

METiS TechBio, an AI-driven drug design start-up, made a strong debut on the Hong Kong stock market, raising HK$2.11 billion. CEO Lai Tsai-Ta compared the company to SpaceX, highlighting its use of AI algorithms for rapid drug development through nano-delivery platforms.